---
id: eu_mdr-临床背景信息sota
title:
  zh: 临床背景信息(SOTA)
  en: ''
regulation: eu_mdr
category: eu_mdr/mdcg
status: active
source_url: https://reguverse.com/documentation/clinical-evaluation/cep/sota/
source_url_verified: '2026-02-23'
source_url_status: migrated
source_format: html
translation: original
last_verified: '2026-02-23'
contributor: RASAAS
migrated_from: wordpress
wordpress_id: 4356
effective_date: '2025-05-28'
---

# 临床背景信息(SOTA)

临床评价计划（CEP）中的“临床背景信息 (State-of-the-Art, SOTA)”章节，是确立待评价医疗器械临床价值和定位的关键环节。本章的核心目标是系统、客观地阐述与器械相关的当前医学知识体系和临床实践标准。通过对相关疾病、现有诊疗手段、可替代方案及其公认安全性和有效性水平的清晰界定，SOTA为后续临床评价的范围、终点选择和可接受标准的设定提供了必要的基准。

## **临床背景 (Clinical Background)**

此部分为待评价器械所应用的特定医学领域构建一个清晰、全面的认知框架。

首先，需要精确界定与器械预期用途直接相关的**特定医学状况或疾病** 。这包括对该疾病的**定义、流行病学特征** （如患病率、发病率，以及相关的人口统计学特征如年龄、性别分布）、主要的**风险因素** 和公认的**病理生理机制** 进行系统性描述。随后，应详细阐述该疾病的**临床表现谱系** ，从早期或无症状阶段，到疾病进展后的各种典型症状和体征，直至最严重的临床阶段。此外，对疾病的自然病程、发展趋势和总体预后也应有所说明。所有这些描述均需基于当前公认的医学文献和权威数据，并规范引用来源。

在对疾病概况进行清晰阐述后，应过渡到对当前临床实践中存在的**挑战和未满足的临床需求** 进行分析。这要求识别并阐明在现有诊疗模式下，针对该疾病的诊断、治疗或长期管理等方面仍然存在的不足或难题。例如，这可能涉及特定患者亚群的诊断准确性问题，不同治疗技术快速发展背景下临床实践标准的不统一，或在某些精细操作层面缺乏标准化指南。此外，现有治疗方法在提升远期疗效方面的局限，医疗资源配置不均导致的诊疗可及性差异，或特定病理改变给临床操作带来的技术壁垒等，均是值得探讨的方面。准确识别这些未满足的需求，有助于后续论证待评价器械的潜在临床贡献。

然后，需要系统概述针对该疾病的**现有诊断方法和标准化流程** 。应从基础的临床评估（包括详细的病史采集和体格检查）入手，逐步介绍并评估各项核心的无创及有创诊断技术。在此过程中，应结合并引用相关专业学会发布的临床指南（如NICE, ACC/AHA, ESVS等）中关于诊断路径的推荐，以体现当前规范化的诊断实践。

在诊断方法之后，应详尽阐述针对该疾病的**主流治疗策略及公认的“金标准”疗法** （如有）。这通常始于对基础性、综合性治疗措施的介绍，如生活方式干预（例如戒烟指导）、危险因素的系统管理（例如控制高血压、糖尿病、高脂血症）以及核心的药物治疗方案（例如抗血小板药物、他汀类药物的应用）。针对疾病的不同分期、分型或严重程度，应分别阐述其推荐的治疗方案和层级。在讨论各种治疗方案时，还应分析其选择的循证医学依据，如患者风险分层、病变解剖特点等。引用权威临床指南的推荐意见是确保这部分内容专业性的关键。

最后，对于与待评价器械类型相关（或由其辅助的关键医疗程序）的临床应用，须明确阐述行业内公认的、用于评估其安全性和性能的临床终点。同时，也需全面审视相关的安全性终点，如围手术期并发症和远期不良事件。若器械本身具有特定的性能参数对其临床应用非常关键，则应一并讨论这些参数，以及可能由器械直接导致的特有不良事件，并结合标准操作规范和使用建议进行说明。在阐述这些终点时，应尽可能提供来自已发表文献或指南的、具有代表性的**量化数据或可接受范围** 。适时采用表格形式总结关键国际指南的核心推荐或重要数据。

## **可替代治疗方案 (Alternative Options)**

本节旨在客观、全面地介绍除待评价器械（或其相关疗法）之外，当前临床上可用的其他**可替代治疗方案** 。

首先，应对这些替代方案进行**系统的梳理和描述** 。根据其性质，这些方案可大致归类为：

  * **保守治疗或非干预性管理**
  * **其他类型的介入或外科治疗技术**
  * **其他可能相关的辅助或特殊治疗手段**

在对各种替代方案进行充分描述之后，核心环节是进行**审慎的对比分析** 。这意味着需要将待评价器械（或其所支持的核心治疗程序）与这些替代方案，在公认的关键安全性和性能临床终点上进行客观的比较。此类比较必须基于高质量的循证医学证据，如已发表的随机对照试验（RCTs）、系统评价（Systematic Reviews）和荟萃分析（Meta-analyses），以及权威临床指南的推荐。清晰、规范地引用这些证据来源至关重要。在叙述复杂的对比数据时，辅以设计良好的表格进行总结，可以显著增强信息的可读性和影响力。进行对比分析时，必须保持中立和客观，既要合理呈现待评价器械（或其相关疗法）相较于部分替代方案可能存在的临床获益或特点，也要如实反映其可能存在的不足，或与其他成熟方案在效能与安全性上的可比性。

* * *

The “Clinical Background (State-of-the-Art, SOTA)” chapter within the Clinical Evaluation Plan (CEP) is a critical segment for establishing the clinical value and positioning of the medical device under evaluation. The core objective of this chapter is to systematically and objectively articulate the current body of medical knowledge and standard clinical practices relevant to the device. By clearly defining the associated disease(s), existing diagnostic and therapeutic modalities, alternative treatment options, and their generally accepted levels of safety and performance, the SOTA provides essential context and benchmarks for the subsequent determination of the clinical evaluation’s scope, endpoint selection, and acceptance criteria.

## **Clinical Background**

This section is dedicated to constructing a clear and comprehensive cognitive framework for the specific medical field in which the device under evaluation will be applied.

Firstly, the **specific medical condition or disease** directly related to the device’s intended use must be precisely defined. This involves a systematic description of the disease’s **definition, epidemiological characteristics** (such as prevalence, incidence, and relevant demographic features like age and gender distribution), primary **risk factors** , and recognized **pathophysiological mechanisms**. Subsequently, the **spectrum of clinical manifestations** of the disease should be detailed, progressing from early or asymptomatic stages, through various typical signs and symptoms as the disease advances, to the most severe clinical phases. Furthermore, information on the natural history, progression, and overall prognosis of the disease should be included. All such descriptions must be grounded in currently accepted medical literature and authoritative data, with appropriately cited sources.

Following a clear exposition of the disease overview, the narrative should transition to an analysis of the **existing challenges and unmet clinical needs** within current clinical practice. This requires identifying and articulating the deficiencies or difficulties that persist in the diagnosis, treatment, or long-term management of the disease under the prevailing healthcare models. For instance, this might involve issues with diagnostic accuracy in specific patient subgroups, inconsistencies in clinical practice standards amidst the rapid evolution of different treatment technologies, or a lack of standardized guidelines for certain refined procedures. Additionally, limitations in enhancing long-term efficacy with current treatment methods, disparities in access to diagnosis and treatment due to uneven resource allocation, or technical barriers posed by specific pathological changes are all aspects worthy of discussion. Accurately identifying these unmet needs helps to subsequently substantiate the potential clinical contribution of the device under evaluation.

Next, a systematic overview of **current diagnostic methods and standardized procedures** for the disease is required. This should begin with fundamental clinical assessments (including detailed history taking and physical examination) and progressively introduce and evaluate core non-invasive and invasive diagnostic techniques. Throughout this process, recommendations from relevant professional society clinical guidelines (e.g., NICE, ACC/AHA, ESVS) concerning diagnostic pathways should be integrated and cited to reflect current standardized diagnostic practice.

Subsequent to diagnostic methods, **mainstream therapeutic strategies and recognized “gold standard” therapies** (if any exist) for the disease should be exhaustively detailed. This typically begins with an introduction to foundational, comprehensive treatment measures, such as lifestyle interventions (e.g., smoking cessation advice), systematic management of risk factors (e.g., control of hypertension, diabetes, hyperlipidemia), and core pharmacological treatment regimens (e.g., application of antiplatelet agents, statins). For different stages, types, or severities of the disease, their respective recommended treatment plans and hierarchical approaches should be elucidated. When discussing various treatment options, the evidence-based rationale for their selection, such as patient risk stratification and anatomical lesion characteristics, should also be analyzed. Citing recommendations from authoritative clinical guidelines is key to ensuring the professionalism of this section.

Finally, concerning the clinical application related to the type of device under evaluation (or the key medical procedure it facilitates), it is imperative to clearly articulate the industry-accepted clinical endpoints used to assess its safety and performance. If the device itself has specific performance parameters crucial to its clinical application, these parameters should be discussed along with any unique adverse events directly attributable to the device, explained in conjunction with standard operating procedures and usage recommendations. When presenting these endpoints, **quantitative data or acceptable ranges** from published literature or guidelines should be provided whenever possible. The appropriate use of tables to summarize core recommendations from key international guidelines or significant data can enhance the efficiency and clarity of information delivery.

## **Alternative Options**

This section aims to objectively and comprehensively present other currently available **alternative treatment options** in clinical practice, aside from the device under evaluation (or its related therapy).

Firstly, these alternative options should be **systematically reviewed and described**. Depending on their nature, these options can be broadly categorized as:

  * **Conservative treatment or non-interventional management**
  * **Other types of interventional or surgical treatment technique**
  * **Other potentially relevant adjunctive or special treatment modalities**

Following a thorough description of the various alternative options, the core element is to conduct a **judicious comparative analysis**. This entails objectively comparing the device under evaluation (or the core therapeutic procedure it supports) with these alternatives against recognized key clinical endpoints for safety and performance. Such comparisons must be based on high-quality, evidence-based medicine, such as published randomized controlled trials (RCTs), systematic reviews, and meta-analyses, as well as recommendations from authoritative clinical guidelines. Clear and standardized citation of these evidence sources is crucial. When narrating complex comparative data, supplementing with well-designed tables for summary can significantly enhance the readability and impact of the information. When conducting comparative analysis, neutrality and objectivity must be maintained, reasonably presenting potential clinical benefits or characteristics of the device under evaluation (or its related therapy) compared to some alternatives, while also truthfully reflecting its possible shortcomings or its comparability in efficacy and safety with other established options.
